ARCHIVES

Dendreon Claims “Clear Hit” On Provenge, But Skeptics Await Data Presentation

This article is from The Cancer Letter archive.

Vol. 35 No. 15 | April 17, 2009

Download PDF Visit The Full Archive

Related Articles

U.S. Cigarette Sales Dropped 4.2 Percent Last Year

March 31, 2006

Final Money Bill Clear On Permitting New Construction Funding

December 12, 1975

Tarceva Reaches Endpoint Early: Longer PFS Than Chemo Alone

February 25, 2011

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

June 3, 2005

In Aftermath of NEJM Article, Critic Bailar Declares The Defeat Of Cancer Treatment

June 6, 1997

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985